Document Detail


Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.
MedLine Citation:
PMID:  23299860     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSION: These findings suggest that cell line models maintain the molecular background of HCC and that subtype may be important for selecting patients for response to novel therapies. In addition, it highlights a potential role for Src family signaling in this progenitor subtype of HCC.
Authors:
Richard S Finn; Alexey Aleshin; Judy Dering; Peter Yang; Charles Ginther; Amrita Desai; Danyun Zhao; Erika von Euw; Ronald W Busuttil; Dennis J Slamon
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-04-01
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  57     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-23     Completed Date:  2013-07-05     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1838-46     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 American Association for the Study of Liver Diseases.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Apoptosis / drug effects
Carcinoma, Hepatocellular / drug therapy*,  genetics*
Cell Cycle / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic / drug effects
Humans
Liver Neoplasms / drug therapy*,  genetics*
Male
Pharmacogenetics
Protein Kinase Inhibitors / pharmacology,  therapeutic use*
Pyrimidines / pharmacology,  therapeutic use*
RNA, Small Interfering / pharmacology
Thiazoles / pharmacology,  therapeutic use*
src-Family Kinases / antagonists & inhibitors*,  drug effects,  genetics
Chemical
Reg. No./Substance:
0/Protein Kinase Inhibitors; 0/Pyrimidines; 0/RNA, Small Interfering; 0/Thiazoles; EC 2.7.10.2/src-Family Kinases; RBZ1571X5H/dasatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Voice conversion in cochlear implantation.
Next Document:  Lactic acidosis in patients with diabetes.